“In this systematic review, cannabinoid-based therapies showed lower neuropsychiatric symptom and agitation scores than placebo in patients with moderate-to-severe AD.”
Archives: News Releases
Since 1992, every Thursday and when breaking news warrants, NORML | The NORML Foundation have been issuing weekly press releases for marijuana law supporters and the media.
NORML’s News Releases archives goes back to 1996 and serves as a valuable tool to alert citizens about cannabis-related news and legislation as well as a research tool for reviewing a chronology of marijuana law reform.
Of the 937 products evaluated, only 31 percent contained percentages of CBD that were within ±10 percent of what was advertised on the products’ labels.
Over 95 percent of the study’s participants ceased their use of opioids by the conclusion of the study.
Investigators identified “meaningful benefits” in patients’ sleep quality, pain, and nocturnal urinary frequency following cannabis treatment.
Taxes derived from the licensed sale of state-regulated adult-use cannabis products totaled more than $4.5 billion in 2025 – the highest amount ever recorded in a single year.
State-licensed retailers will begin selling cannabis products to those age 21 or older on July 1, 2027.
“Our findings fit within the broader literature showing that improved access to symptom-relieving treatments can affect labor market outcomes.”
“Cannabis-based medicines may offer an alternative to traditional treatments,” researchers concluded.